Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Zoltan! who wrote (27283)	1/6/1999 11:55:00 PM
From: John Zwiener	Read Replies (1) \| Respond to of 32384

Did anyone mention this? My eyes glaze over when I try to read this thread. So does this qualify as an additional indication so that ligand gets 3% royalty? •FDA Will Allow Eli Lilly and Company (LLY) To Promote Link Between Evista And Lower Cancer Risk The Food and Drug Administration approved a package-labeling change for Eli Lilly & Co.'s osteoporosis drug Evista that will allow the company's sales personnel to refer to research studies showing the drug is associated with a reduced risk of breast cancer. The new labeling stops short of suggesting that Evista be prescribed for the prevention of breast cancer, but it certainly provides a boost to Lilly's sales efforts. Lilly holds high hopes for Evista, and some analysts have predicted that it will reach $1 billion or more a year in sales.

To: Zoltan! who wrote (27283)	1/7/1999 12:02:00 AM
From: John Zwiener	Respond to of 32384

This press release preceded the FDA approval for cancer risk reduction indication. The study seems to show a 63% reduction over 3 years from invasive CA and reduction in cholesterol, in addition to reducing osteoporosis. Unless there is new drug recently that has this combination of benefits, this would put Evista in a good position. Any comments? prnewswire.com